果糖注射液临床使用的合理性及代谢风险分析

Rationality and metabolic risk analysis of fructose injection in clinical

目的了解果糖注射液在医院的使用情况并对其合理性及代谢风险进行分析,为临床用药安全性提供参考,辅助临床合理用药。方法采用回顾性研究,随机抽取医院2015年9月-2016年8月静脉应用果糖注射液的住院病例1 000份,从患者血脂、血尿酸、体质量指数及肝肾功能等多方面进行统计分析。结果果糖注射液用于高脂血症患者299例,其中253例以三酰甘油升高为主;高尿酸血症145例;14.60%为肥胖患者,6.50%为脂肪肝患者;超过半数的患者合并有肝或肾脏疾病;可用生理盐水替代溶媒的无果糖注射液适应证患者有115例。结论医院果糖注射液使用存在一定的不合理性,临床应用时需结合患者疾病的基础情况,提高临床用药的安全性,避免潜在的代谢风险。

Objective To understand the use of fructose injection in hospitals and analyze its rationality and metabolic risk,provide reference for clinical drug safety,and assist clinical rational drug use.Methods Using retrospective studies,randomly selected 1 000 hospitalized cases of intravenous fructose injection from September 2015 to August 2016.Statistical analysis was carried out from various aspects such as blood lipids,uric acid,body mass index and liver and kidney function of patients.Results There were 299 cases of hyperlipidemia in patients taking fructose injection,of which 253 cases were mainly increased by triglyceride;145 cases were hyperuricemia;14.60% were obese patients,and 6.50% were fatty liver patients;More than half of the patients had liver or kidney disease;115 patients had no fructose indications that could replace the vehicle with saline.Conclusion Unreasonable situations are existed and comprehensive evaluation of the patience is needed to prevent metabolic risk and improve the safety use of fructose injection in the hospital.